October 21st, 2020 | 12:42 CEST
BioNTech, Valeo Pharma, Pfizer - Starting signal!
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
On the home stretch!
Pfizer pushes forward. The U.S. pharmaceutical Company could apply for emergency approval of its Corona vaccine in the USA in November. According to Pfizer CEO Albert Bourla, the prerequisite is that efficacy and safety data are positive in the ongoing trials. An emergency approval would have the advantage that parts of the U.S. population, namely, the elderly or medical staff, could be vaccinated even before the official license.
The third week of November as the target
The North Americans, who are developing the active ingredient BNT162b2 in collaboration with the Mainz-based Company BioNTech, are aiming for the third week of November to apply for approval. Since the FDA requires data from at least half of the participants in the ongoing trials for a period of two months after the completion of vaccination, this would be the timeframe for an evaluation.
Most promising applicant
The vaccine from Pfizer and BioNTech is still considered one of the most promising in the fight against the virus. At the beginning of the month, the European Medicines Agency (EMA) confirmed that the testing of the active ingredient in the so-called rolling review process for approval in Europe. Similarly far as the German-American conglomerate, is the U.S. biotech Company, Moderna. The Company intends to apply for emergency approval in December. It remains exciting in the global battle for the "Corona contest."
Alternatives to vaccination
It remains to be seen how long it will take until a suitable vaccine is available on the market for all population groups and whether it is the final elimination of the pandemic. What each individual can do for himself, however, is to strengthen his immune system. For once, even the highly decorated virologists agree on this. It is also undisputed that viruses and pathogens can attack the body easier if the immune system is weak. One can bring about strengthening with healthy foods and drinks.
Nutritional supplements have a targeted effect
People who are healthy and eat a healthy and varied diet mostly supply their bodies with all the vitamins and minerals they need. Under certain circumstances, however, food supplements may be necessary. After operations, in the case of unbalanced nutrition, during pregnancy, or in the case of senior citizens, an undersupply of essential nutrients can occur.
At the pulse of time
Valeo Pharma is well in the running here. The Canadian Company markets a dietary supplement containing a highly effective antioxidant intended to support the immune system. The product is HesperCo and was approved by the Canadian authorities a few weeks ago. At the beginning of November, the capsules will be on the shelves of all major retailers in Canada.
President and Chief Executive Officer of Valeo Pharma, Steve Saviuk, commented as follows: "We have high expectations for HesperCo, which will be launched nationally in the coming weeks, as the immune support it provides is needed in the current health care environment. We continue interacting with Health Canada in the review of Redesca (low-molecular-weight Heparin biosimilar) and are preparing for an early 2021 launch, pending its expected approval."
In addition to HesperCo, the North Americans market innovative prescription products with a focus on neurodegenerative diseases, oncology products, and speciality products for hospitals in Canada. At the end of September, a total of CAD 6.9 million has been raised from investors. The money raised is to strengthen sales and fill the pipeline of future-oriented products.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.